Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: Impact and implications for other countries

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 2, 2010, Pages 199-207

  Godman, Brian ^a,b,c   Bucsics, Anna ^d   Burkhardt, Thomas ^d   Schmitzer, Manuela ^d   Wettermark, Björn ^a   Wieninger, Peter ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Hauptverband der Sterreichischen Sozialversicherungsträger ^*  (Austria)

Author keywords

Austria; Drug expenditure; Drug utilization; Generics; Pharmaceuticals; Reforms

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PROTON PUMP INHIBITOR; RAMIPRIL;

AMBULATORY CARE; ARTICLE; AUSTRIA; COST BENEFIT ANALYSIS; DRUG COST; DRUG LEGISLATION; DRUG UTILIZATION; GOVERNMENT REGULATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; PRESCRIPTION; SOCIAL INSURANCE;

AMBULATORY CARE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AUSTRIA; DATABASES, FACTUAL; DIURETICS; DRUG COSTS; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; HEALTH CARE REFORM; HUMANS; NATIONAL HEALTH PROGRAMS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 77951012987     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.6     Document Type: Article

References (42)

1. Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European healthcare systems - a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138 (2008).
2. Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoeconomics Outcomes Res. 9(1), 65-83 (2009).
3. Comma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev. Pharmacoeconomics Outcomes Res. 9(6), 569-581 (2009).
4. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7-24 (2010).
5. Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics 27, 435-438 (2009).
6. Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26, 91-98 (2008).
7. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 26, 537-550 (2008). (Pubitemid 351871549)
8. Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res. 8(4), 357-371 (2008).
9. Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid lowering drugs: implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res. 9(5), 475-484 (2009).
10. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications Expert Rev. Pharmacoeconomics Outcomes Res. 10(1), 73-85 (2010).
11. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7(3), 1-11 (2009).
12. Leal J, Luengo-Fernandez R, Gray A et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J. 27, 1610-1619 (2006). (Pubitemid 43954923)
13. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens. Res. 28, 385-407 (2005). (Pubitemid 41014801)
14. Gradman A. Evolving the understanding of the renin-angiotensin- aldosterone system: pathophysiology and targets for therapeutic intervention. Am. Heart J. 157, S1-S6 (2009).
15. Mancia G, Laurent S, Agabiti-R et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens 27, 2121-2158 (2009).
16. Matcher D, McCroy D, Orlando L et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin I receptor blockers for treating essential hypertension. Ann. Intern. Med. 148, 16-29 (2008). (Pubitemid 351664943)
17. Lindholm LH, Carlberg B, Samuelsson O. Should b-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366, 1545-1553 (2005). (Pubitemid 41540112)
18. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 27, S65-S67 (2004).
19. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003). (Pubitemid 37553153)
20. Frisk P, Mellgren T-O, Hedberg N et al. Utilization of angiotensin blockers in Sweden combining survey and register data to study adherence to prescribing guidelines. Eur. J. Clin. Pharmacol. 64, 1223-1229 (2008).
21. Dickstein K, Cohen-Solal A, Filippatos G et al.; on behalf of the task force for the Diagnosis and Treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur. Heart J. 29, 2388-2442 (2008).
22. Gradman A, Papademetriou V. Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. Am. Heart J. 157, S17-S23 (2009).
23. Mielniczuk L, Stevenson L. Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in the management of congestive heart failure patients: what have we learnt from recent clinical trials. Curr. Opin. Cardiol. 20, 250-255 (2005). (Pubitemid 40896360)
24. Strippoli G, Craig M, Schena F et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabeteic nephropathy and delay its progression. J. Am. Soc. Nephrol. 17, S153-S155 (2006).
25. Jamerson K, Weber MA, Bakris GL et al.; for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417-2428 (2008).
26. Fletcher A, Palmer A, Bulpitt C. Coughing with angiotensin converting enzyme inhibitors; how much of a problem? J. Hypertens. 12, S43-S47 (1994). (Pubitemid 24212093)
27. Elliot H. Focus on the ONTARGET results. J. Hypertens. 27, S8-S10 (2009).
28. McDowell S, Coleman J, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine BMJ 332, 1177-1181 (2006). (Pubitemid 44365446)
29. Walley T, Folino-Gallo P, Schwabe U, van Ganse E; on behalf of the EuroMedStat group. Variations and increase use of statins across Europe: data from administrative databases. BMJ 328, 385-386 (2004). (Pubitemid 38241189)
30. Cramer JA, Benedict A, Muszabek N et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract. 62, 76-87 (2008). (Pubitemid 350294021)
31. Bangalore S, Kamalakkannan G, Parkar S, Messerli F. Fixed-dose combinations improve medication compliance: a meta analysis. Am. J. Med. 120, 713-719 (2007). (Pubitemid 47176510)
32. Garattini L, Ghislandi S. Off-patent drugs in Italy: a short sighted view? Eur. J. Health Econ. 7, 79-83 (2006).
33. Wettermark B, Pehrsson A, Juhasz- Haverinen M et al. Financial incentives linked to self-assessment of prescribing patterns - a new approach for quality improvement of drug prescribing in primary care. Qual. Prim. Care 17, 179-189 (2009).
34. Wettermark B, Godman B, Neovius M et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 94, 221-229 (2010).
35. Schnneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy 81, 17-28 (2007).
36. Schneeweiss S, Walker A, Glynn R et al. Outcome of reference pricing for angiotensin-converting-enzyme inhibitors. N. Engl. J. Med. 346, 822-829 (2002). (Pubitemid 34984656)
37. Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A. Generic olanzapine: health authority opportunity or nightmare? Expert Rev. Pharmacoeconomics Outcomes Res. 8(6), 549-555 (2008).
38. Wladysiuk M, Araszkiewicz A, Godman B et al. Patient co-payments do influence atypical antipsychotic choice in Poland; implications once generic atypcials are available. Appl. Health Econ. Health Policy (2010) (In Press).
39. Sakshaug S, Furu K, Karlstead O et al. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br. J. Clin. Pharmacol. 64, 476-481 (2007). (Pubitemid 47404299)
40. Fretheim A, Håvelsrud K, MacLennan G et al. The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis. PLoS Med. e232, 1178-1186 (2007). (Pubitemid 47196221)
41. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patient's care. Lancet 362, 1225-1230 (2003). (Pubitemid 37255352)
42. Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 317, 465-468 (1998).